A report released today by RBC Capital Markets about Concordia Healthcare Corp (TSE:CXR) drops the target price to $18.00
- Updated: September 19, 2016
Yesterday Concordia Healthcare Corp (TSE:CXR) traded 0.98% lower at $7.02. The company’s 50-day moving average is $13.53 and its two hundred day average is $28.73. The last close is down 75.46% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the same period. 667,595 shares of the stock were exchanged, down from ann avg. trading volume of 782,538.
In a statement issued on 9/19/2016 RBC Capital Markets fell the target price of Concordia Healthcare Corp (TSE:CXR) from $32 to $18 stating a possible upsideof 1.56%.
On Tuesday September 13 2016, RBC Capital Markets released a statement for Concordia Healthcare Corp(TSE:CXR) bumped the target price from $0.00 to $32.00. At the time, this indicated a possible upside of 2.60%.
See Graph Below:
A total of 10 brokers have released a report on the company. Zero rate the company a strong buy, 0 rate the stock a buy, 0 firms rate the company a hold, 0 rate the stock to underperform, and lastly 0 analystsrate the stock as sell with a 12-month target price of $23.13
Concordia Healthcare Corp has a 52 week low of $6.33 and a 52 week high of $28.35 . The company’s market capitalization is presently $0.0.
About Concordia Healthcare Corp (TSE:CXR)
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, and includes centralized costs incurred by the Company.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.